MicroRNA 199a-5p (miR-199a-5p) (miR-199a-5p)

MicroRNA 199a-5p (miR-199a-5p) is a mature, highly conserved non-coding RNA molecule that plays a pivotal role in the post-transcriptional regulation of gene expression [2]. It is processed from the 5' arm of pre-microRNA precursors transcribed from two distinct genomic loci, MIR199A1 and MIR199A2, located on chromosomes 19 and 1, respectively. Biologically, miR-199a-5p functions by binding to the 3' untranslated regions (UTR) of specific target messenger RNAs, leading to their degradation or translational repression [2, 10]. Its target spectrum includes essential regulatory genes such as HIF1A, mTOR, MET, SIRT1, and Caveolin-1, placing it at the intersection of pathways controlling cell survival, autophagy, and metabolic homeostasis [5, 8, 9]. In human disease, miR-199a-5p exhibits a context-dependent role; it often functions as a tumor suppressor in malignancies like hepatocellular carcinoma and bladder cancer, but promotes pathogenesis in liver fibrosis, atherosclerosis, and type 2 diabetes [1, 2, 4, 9]. In the cardiovascular system, miR-199a-5p is specifically associated with pathological hypertrophy and metabolic dysfunction, distinct from the regenerative properties of its sister strand, miR-199a-3p [2, 4]. Therapeutic development focuses on synthetic mimics to restore its suppressive activity in oncology and antagomirs to inhibit its pro-fibrotic and pro-atherogenic effects [1, 11].

Other names

hsa-miR-199a-5pMIR199A1MIR199A2MicroRNA 199amiRNA 199a-5p

Synthetic mimics restore the endogenous miRNA's inhibitory function by binding to the 3' untranslated region (UTR) of target mRNAs (e.g., HIF1A, mTOR, MET), leading to mRNA degradation or translational repression. In contrast, antagomirs or antisense oligonucleotides competitively bind to the mature miR-199a-5p sequence to inhibit its activity, thereby de-repressing its target genes to improve conditions like insulin sensitivity or hepatic lipid metabolism.